Tumor Marker: a biomarker found in the body system that can be elevated by the presence of all types of cancer. Each tumor marker is indicative of a particular disease process, and are used in oncology to help detect the presence of cancer.
Date: January 28, 2021 Time: 7:00am (PST), 10:00am (EST) Many of the newly recognized clinically significant genetic markers in pediatric leukemias cannot be reliably detected by routine dia...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...
Background and aim: Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platf...
DATE: April 28, 2020 TIME: 10:00am PT All cells release extracellular vesicles (EVs) that can carry molecular cargo to other cells to affect their function. EVs are promising as potential bi...
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
DATE: April 2, 2020 TIME: 8:00am PT, 11:00am ET Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. We recently identified a hepatocellular carcinoma (HCC)...
DATE: November 7, 2019TIME: 10:00am PST, 1:00pm EST Studying the pathogenesis of diabetes requires detailed analysis of the pancreatic islet microenvironment and its numerous c...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Early detection is critical for improved survival in melanoma. Melanocytic nevi are extremely common benign tumors that mimic melanoma and are therefore commonly biopsied. Currently, the dete...
Date: January 28, 2021 Time: 7:00am (PST), 10:00am (EST) Many of the newly recognized clinically significant genetic markers in pediatric leukemias cannot be reliably detected by routine dia...
Dr. Bacher will be discussing the history and evolution of MSI, the differences between popular testing methods, and what the future holds for this powerful biomarker....
DATE: October 8, 2020 TIME: 1:00pm PDT Microsatellite instability (MSI) has evolved as a marker of potential hereditary cancer risk and is now a tissue agnostic immune biomarker with a broad...
DATE: September 15, 2020 TIME: 08:00am PT Tumorigenesis and cancer progression are affected by the tumor immune microenvironment (TIME). The TIME not only influences the efficiency of existi...
DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
DATE: June 30, 2020 TIME: 8:00am PT, 11:00am Understanding the tumor microenvironment (TME) is essential for the development of effective treatments for cancer patients. Traditional multi...
Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
The RNAscope in situ hybridization technology allows high sensitivity, specificity and spatial resolution providing pivotal single-cell gene expression information to gain better insights in...
A key step in the clinical production of CAR T cells is the expansion of engineered T cells. To generate enough cells for viable adoptive cell therapy, cells must be robustly stimulated, whi...
Cancer cells can acquire immune resistance resulting in a loss of immunosurveillance. Tumor cells can upregulate PDL-1 which binds to PD-1. This complex inhibits CD8 Tumor Infiltrating cells...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Programmed death-1 (PD-1) inhibits T and B cell function upon ligand binding. PD-1 blockade revolutionized cancer treatment, and while numerous patients respond, some develop autoimmune-like...
Increasing evidence suggests that targeted sequencing of cell free DNA (cfDNA) can provide a comprehensive molecular portrait of solid tumors. However, the concordance between tissue and cfD...
DATE: May 8, 2020 TIME: 8:00am PT, 11:00am ET Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indic...
Background and aim: Multiplexing of biomarker panels by microsphere-based technologies are robust and cost-effective methods. The QuantiGene™ Plex Assay (ThermoFisher Scientific) platf...
DATE: April 28, 2020 TIME: 10:00am PT All cells release extracellular vesicles (EVs) that can carry molecular cargo to other cells to affect their function. EVs are promising as potential bi...
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
DATE: April 2, 2020 TIME: 8:00am PT, 11:00am ET Cyclins A2 and E1 regulate the cell cycle by promoting S phase entry and progression. We recently identified a hepatocellular carcinoma (HCC)...
DATE: November 7, 2019TIME: 10:00am PST, 1:00pm EST Studying the pathogenesis of diabetes requires detailed analysis of the pancreatic islet microenvironment and its numerous c...
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Early detection is critical for improved survival in melanoma. Melanocytic nevi are extremely common benign tumors that mimic melanoma and are therefore commonly biopsied. Currently, the dete...